Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:11:55.642Z.
Calculation as of: 2026-10-06T16:11:55.642Z.
Quote observation: 2026-10-06T16:10:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869772d5b15fe2f366f7470de3318cdd420f1d22994776f46b79eb6f67ec6a89
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Eupraxia Pharmaceuticals Inc.
Market Cap
$267.51M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$268.17M
EV/EBITDA Ratio
N/A
TTM Avg
2.41x
3Y Avg
3817.71x
5Y Avg
2177.76x
Market Cap
$266.71M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$267.87M
EV/EBITDA Ratio
N/A
TTM Avg
10.21x
3Y Avg
10.21x
5Y Avg
10.68x
Market Cap
$261.87M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.22M
EV/EBITDA Ratio
N/A
TTM Avg
128764.90x
3Y Avg
128764.90x
5Y Avg
128764.90x
Market Cap
$274.62M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$277.05M
EV/EBITDA Ratio
N/A
TTM Avg
71.43x
3Y Avg
71.43x
5Y Avg
71.43x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $267.51M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $268.17M | N/A | 2.41x | 3817.71x | 2177.76x |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.71M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.87M | N/A | 10.21x | 10.21x | 10.68x |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $261.87M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $261.22M | N/A | 128764.90x | 128764.90x | 128764.90x |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.05M | N/A | 71.43x | 71.43x | 71.43x |
| AC Immune S.A. (ACIU)vs › | $256.77M | N/A | 15.20x | 12.43x | 15.17x |
| Fate Therapeutics, Inc. (FATE)vs › | $277.46M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
